USMLE Step 1 practice question: Acyclovir-resistant HSV: thymidine kinase deficiency

USMLE Step 1MicrobiologyPharmacology

A 41-year-old man with HIV infection comes to the clinic because of painful perianal sores for 6 weeks. He has had poor adherence to antiretroviral therapy for the past year. Three weeks ago, he was prescribed oral valacyclovir at treatment doses, which he has taken as directed without improvement. He has a 20-pack-year smoking history and does not use illicit drugs. His temperature is 37.4°C (99.3°F), pulse is 84/min, and blood pressure is 122/76 mm Hg. Examination shows several shallow, coalescing perianal ulcers with scalloped borders on an erythematous base; there is tender inguinal lymphadenopathy. His CD4+ T-lymphocyte count is 38/mm3. PCR of a swab from the ulcer base is positive for herpes simplex virus type 2. Phenotypic antiviral susceptibility testing of the isolate shows resistance to acyclovir and penciclovir and susceptibility to foscarnet and cidofovir.

Which of the following best explains the drug resistance of this patient's viral isolate?

  1. Deficient viral thymidine kinase activity
  2. Altered viral neuraminidase active site
  3. Altered viral reverse transcriptase
  4. Deficient viral UL97 protein kinase activity
  5. Increased drug efflux by host P-glycoprotein
Show answer and explanation

Correct answer: A. Deficient viral thymidine kinase activity

Chronic, nonhealing perianal HSV-2 ulcers in a patient with advanced HIV infection (CD4+ count <50/mm3) that fail to respond to adequate valacyclovir therapy suggest acyclovir-resistant HSV. Valacyclovir is a prodrug that is rapidly converted to acyclovir. Acyclovir (like penciclovir, the active form of famciclovir) is a guanosine analog that must first be monophosphorylated by the virus-encoded thymidine kinase (TK); host cellular kinases then convert it to the triphosphate. Acyclovir triphosphate competitively inhibits viral DNA polymerase and, once incorporated into viral DNA, causes chain termination because it lacks a 3'-hydroxyl group. Because only infected cells express viral TK, the drug is selectively activated in infected cells, which explains its low toxicity.

About 95% of clinical acyclovir-resistant HSV isolates carry mutations in the UL23 gene that cause absent (TK-deficient) or reduced TK activity or altered substrate specificity; mutations in the viral DNA polymerase (UL30) are much less common. Resistance occurs mainly in immunocompromised patients with high viral replication and prolonged drug exposure. TK-deficient strains are cross-resistant to all TK-dependent drugs (acyclovir, valacyclovir, famciclovir/penciclovir, ganciclovir) but remain susceptible to drugs that do not require viral TK activation: foscarnet, a pyrophosphate analog that binds directly to the pyrophosphate-binding site of viral DNA polymerase, and cidofovir, a nucleotide (phosphonate) analog that is phosphorylated only by host kinases. Preserved susceptibility to both foscarnet and cidofovir argues against a DNA polymerase mutation, which can confer cross-resistance to these agents.

Foscarnet is the usual treatment for acyclovir-resistant HSV; its major toxicities are nephrotoxicity and electrolyte disturbances (hypocalcemia, hypomagnesemia, hypokalemia, hypo- or hyperphosphatemia) that can cause seizures. Cidofovir is nephrotoxic and is given with probenecid and intravenous saline.

High-yield summary: Acyclovir-resistant HSV/VZV is most often due to loss of viral thymidine kinase → treat with foscarnet (or cidofovir), which bypasses viral TK.

Why the other options are wrong

  • B. Altered viral neuraminidase active site — Neuraminidase mutations (eg, H275Y in influenza N1) confer resistance to neuraminidase inhibitors such as oseltamivir. HSV does not use a neuraminidase, and acyclovir does not target one.
  • C. Altered viral reverse transcriptase — Reverse transcriptase mutations (eg, M184V) cause HIV resistance to nucleoside reverse transcriptase inhibitors. HSV is a double-stranded DNA virus that replicates with its own DNA polymerase and does not use reverse transcriptase.
  • D. Deficient viral UL97 protein kinase activity — UL97 is a cytomegalovirus-encoded protein kinase that performs the initial phosphorylation of ganciclovir; UL97 mutations are the most common cause of ganciclovir-resistant CMV. The virus here is HSV-2, which activates acyclovir with its own thymidine kinase.
  • E. Increased drug efflux by host P-glycoprotein — Increased efflux by P-glycoprotein (MDR1) is a mechanism of cancer cell resistance to chemotherapy. It is not a clinically important mechanism of HSV resistance and would not explain selective resistance to TK-dependent drugs with preserved susceptibility to foscarnet and cidofovir.

Key point

Acyclovir requires initial phosphorylation by viral thymidine kinase; HSV resistance is most often due to thymidine kinase deficiency, and such strains are treated with foscarnet, which inhibits viral DNA polymerase without needing activation.

Memory hook

Acyclovir needs the virus's own key — thymidine kinase — to switch on. Lose the key → resistance. Foscarnet is keyless; CMV's key is UL97.

Share: Telegram WhatsApp X LinkedIn

Practice like this every day

15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.

Play free

More free questions in this system

Cryptococcal meningitis: flucytosine mechanism (conversion to 5-fluorouracil)USMLE Step 1 · MicrobiologyAcute uncomplicated cystitis in a nonpregnant woman: 5-day nitrofurantoinUSMLE Step 2 CK · MicrobiologyChronic aortic regurgitationUSMLE Step 1 · CardiovascularPharmacokinetics: volume of distribution and oral loading doseUSMLE Step 1 · PharmacologyAutosomal recessive recurrence risk (cystic fibrosis, unaffected sibling = 2/3 carrier)USMLE Step 1 · GeneticsCisplatin toxicity (ototoxicity, nephrotoxicity, hypomagnesemia): DNA cross-linkingUSMLE Step 1 · Hematology/Oncology

All free questions →